Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study)

Gyuri Kim, Soo Lim, Hyuk Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon Kyu Lee

Research output: Contribution to journalArticle

Abstract

Aim: To investigate the efficacy and safety of evogliptin compared with linagliptin in patients with type 2 diabetes. Materials and Methods: In this 12-week, multicentre, randomized, double-blind, active-controlled, and 12-week open-label extension study, a total of 207 patients with type 2 diabetes who had HbA1c levels of 7.0%-10.0% were randomized 1:1 to receive evogliptin 5 mg (n = 102) or linagliptin 5 mg (n = 105) daily for 12 weeks. The primary efficacy endpoint was the change from baseline HbA1c at week 12. The secondary endpoint was the change in the mean amplitude of glycaemic excursion (MAGE) assessed by continuous glucose monitoring. In the extension study conducted during the following 12 weeks, evogliptin 5 mg daily was administered to both groups: evogliptin/evogliptin group (n = 95) and linagliptin/evogliptin group (n = 92). Results: After 12 weeks of treatment, the mean change in HbA1c in the evogliptin group and in the linagliptin group was −0.85% and −0.75%, respectively. The between-group difference was −0.10% (95% CI: −0.32 to 0.11), showing non-inferiority based on a non-inferiority margin of 0.4%. The change in MAGE was −24.6 mg/dL in the evogliptin group and −16.7 mg/dL in the linagliptin group. These values were significantly lower than the baseline values in both groups. However, they did not differ significantly between the two groups. In the evogliptin/evogliptin group at week 24, HbA1c decreased by −0.94%, with HbA1c values of <7.0% in 80.2% of the patients. The incidence and types of adverse events were comparable between the two groups for 24 weeks. Conclusion: In this study, the glucose-lowering efficacy of evogliptin was non-inferior to linagliptin. It was maintained at week 24 with a 0.94% reduction in HbA1c. Evogliptin therapy improved glycaemic variability without causing any serious adverse events in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)1527-1536
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume22
Issue number9
DOIs
Publication statusPublished - 2020 Sep 1

Keywords

  • continuous glucose monitoringdipeptidyl peptidase-4 inhibitorevogliptinglycaemic variabilitylinagliptintype 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study)'. Together they form a unique fingerprint.

  • Cite this

    Kim, G., Lim, S., Kwon, H. S., Park, I. B., Ahn, K. J., Park, C. Y., Kwon, S. K., Kim, H. S., Park, S. W., Kim, S. G., Moon, M. K., Kim, E. S., Chung, C. H., Park, K. S., Kim, M., Chung, D. J., Lee, C. B., Kim, T. H., & Lee, M. K. (2020). Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study). Diabetes, Obesity and Metabolism, 22(9), 1527-1536. https://doi.org/10.1111/dom.14061